Navigation Links
Sigma-Aldrich Joins Phase 2 of The RNAi Consortium to Validate shRNA Libraries
Date:5/7/2008

RNAi reagents guaranteed to work out of the box. Sigma-Aldrich will also expand its program to promote and educate the research community about the multiple applications of RNAi technology by providing educational tools and forums.

"Sigma-Aldrich is committed to the development of RNAi technology. Through our collaboration with TRC2, we're producing the most highly validated shRNA libraries available to the research community," said Dave Smoller, President of Sigma-Aldrich's Research Biotech Business Unit. "By making these tools available to researchers worldwide, Sigma-Aldrich is facilitating advanced disease and drug discovery research."

Lentiviral-based shRNA libraries enable researchers to study gene function and disease, both in standard cell lines and recognized difficult cell types such as primary, non-dividing, growth-arrested or terminally differentiated cells. Such cell lines are typically not amenable to standard transfection or genomic integration by other viral delivery systems, but they may be transduced efficiently with lentiviral particles.

"Over the coming years, The RNAi Consortium intends to build upon its successes with shRNA to facilitate loss-of-function genetic screens in mammalian cells," said David Root, Director of the RNAi Platform at the Broad Institute of MIT and Harvard and project leader for TRC2. "The existing TRC library has already proven highly effective for systematic viral-delivery RNAi screening. TRC2 will generate significant further improvements to the library and its applications."

The current MISSION(R) shRNA clone libraries comprise a comprehensive collection of more than 160,000 pre-cloned lentiviral-based shRNA vector constructs targeting more than 16,000 human genes (MISSION TRC-Hs1.0) and 16,000 mouse genes (MISSION TRC-Mm1.0). For more information about the MISSION(R) shRNA clone collections, please visit us online at http://www.sigma.com/tr
'/>"/>

SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sigma-Aldrich to Present at the Baird 2008 Growth Stock Conference on Tuesday, May 13, 2008
2. Sigma-Aldrich to Present at the Bank of America 2008 Healthcare Conference on Tuesday, May 13, 2008
3. Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands
4. Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%.
5. Sigma-Aldrich Corporation 1st Quarter 2008 Earnings Conference Call
6. Sigma-Aldrich Partners With Sunset Molecular Discovery to Expand Your Favorite Gene Search Tool
7. Sigma-Aldrich To Hold Annual Business Review
8. Sigma-Aldrich, Oxford BioMedica and Open Biosystems Settle Patent Dispute Over Use of LentiVector Technology in Research Reagents
9. Sigma-Aldrich and MorphoSys Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies
10. Sigma-Aldrich Names Helge Bastian New VP of Global Marketing for Research Biotech
11. Sigma-Aldrich Announces New Prestige Antibodies(TM) Line for Proteomics and Cell Biology Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital IQ ... Stock Report coverage on MabVax Therapeutics Holdings Inc . ... a clinical stage biotechnology company focused on the development ... needs in the treatment of cancer. MabVax has discovered ... the protective immune responses generated by patients who have ...
(Date:2/26/2015)... N.J. , Feb. 26, 2015 On ... and its affiliated companies, Wilentz, Goldman & Spitzer, ... trade secrets lawsuit against Genewiz Inc. in excess of ... and utilized GenScript,s trade secrets, and that it improperly ... entered an order denying motions for judgment notwithstanding the ...
(Date:2/26/2015)...  23andMe, the leading personal genetics company, today announced ... Officer and Corporate Counsel. Black brings a strong background ... as health care regulations. As a member of the ... reviewing, updating and enhancing the company,s privacy and consent ... joined the company January 5, 2015 and reports to ...
(Date:2/26/2015)... , Feb. 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ... life sciences company that develops and commercializes proprietary technologies ... financial and operational results for the fiscal first quarter ... release are in Canadian dollars (CAD), unless otherwise stated. ... to win new business from our existing customers and ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 323andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
... HONG KONG, April 27, 2012 /PRNewswire-Asia-FirstCall/ -- China Cord Blood ... Company"), the first and largest cord blood banking operator ... a US$65 million convertible debt financing with funds affiliated ... fund managed by Kohlberg Kravis Roberts & Co. L.P. ...
... April 26, 2012  Avaxia Biologics, Inc., a privately-held biotech ... antibody therapeutics for the treatment of gastrointestinal diseases, announced ... Chief Executive Officer of Arisaph Pharmaceuticals, Inc. to its ... that Chris has agreed to serve on our Board," ...
...  Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced ... results on Wednesday, May 2, 2012, after the market closes. ... at 5:00 p.m. ET, which will be open to the ... company will review the financial results and discuss other business ...
Cached Biology Technology:China Cord Blood Corporation Announces Completion of $65 Million Convertible Debt Financing with KKR 2China Cord Blood Corporation Announces Completion of $65 Million Convertible Debt Financing with KKR 3Avaxia Biologics Elects Christopher Kiritsy to its Board of Directors 2Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast 2
(Date:2/5/2015)... Jan. 28, 2015 Research and Markets ... of the "Global Biometrics Market (2014-2020): Market ... Countries " report to their offering. , ... Asia-Pacific is anticipated to overtake ... to increasing government spending towards IT security, government ...
(Date:2/5/2015)... MOUNTAIN VIEW, Calif. , Feb. 3, 2015 ... screen printer technology, demand from industries such as ... the global market for surface mount technology (SMT) ... manual equipment to automatic control will push the ... glue dispensers will remain steady as glue dispensers ...
(Date:1/22/2015)... Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), ... general the State of Washington,s Department ... new enrollment and central issuance system for driver,s licenses and ... The project planning and development will start in January 2015, ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... study presented today at the American College of Cardiology's ... that very intensive cholesterol lowering with a statin drug ... the coronary arteries. , This finding has ... drugs, the most commonly used cholesterol lowering treatment. Previous ...
... rate for the once almost universally fatal childhood cancer ... the near future, thanks to improvements in diagnosis and ... at St. Jude Children's Research Hospital. Almost 4,000 cases ... year, about two-thirds of which are in children and ...
... of a new study provide the first clear proof that ... is wiping out entire frog populations and driving many species ... the journal Nature, the study reveals how the warming may ... to amphibians. The climate-driven fungal disease, the author's say, has ...
Cached Biology News:Intensive statin therapy may partially reverse plaque build-up in arteries 2St. Jude projects 90 percent cure rate for ALL 2St. Jude projects 90 percent cure rate for ALL 3St. Jude projects 90 percent cure rate for ALL 4St. Jude projects 90 percent cure rate for ALL 5Climate change drives widespread amphibian extinctions 2
... Mouse monoclonal [YPF19] to Yersinia ... to detect Yersinia pestis . ... from Yersinia pestis vaccine ... This antibody recognises Y.pestis F1 capsular ...
Phospho-SEK1/MKK4 (Thr261) Antibody...
Rabbit polyclonal to Leucyl tRNA synthetase ( Abpromise for all tested applications). Antigen: L930-H1176 denatured human recombinant LRS. Entrez Gene ID: 3926 Swiss Protein ID: Q9P2J5...
Phospho-FADD (Ser194) Antibody (Human Specific)...
Biology Products: